Skip to main content
OpenTrials

Clinical trial condition

Tetanus

Explore clinical trials studying Tetanus. Study availability and eligibility vary by location and protocol.

225 public trials 6 recruiting studies
Refine in advanced search Browse all conditions

Tetanus trial results

Completed

A Study to Assess the Immunogenicity and Safety of GSK Biologicals' Infanrix-IPV/Hib Vaccine Administered as a Three-dose Vaccination Course at 3, 4.5 and 6 Months of Age and a Booster Dose at 18 Months of Age in Healthy Infants in Russia

NCT02858440

Conditions
Actinomycetales Infections, Bacterial Infections, Bacterial Infections and Mycoses, +25 more
Locations
  • GSK Investigational Site Barnaul, Russia
  • GSK Investigational Site Murmansk, Russia
  • GSK Investigational Site Saint Petersburg, Russia
  • GSK Investigational Site Tomsk, Russia
View Trial Details
Completed

Immunogenicity and Safety Study of Infanrix Hexa in Healthy Infants Born to Mothers Vaccinated With Boostrix™ During Pregnancy or Immediately Post-delivery

NCT02422264

Conditions
Acellular Pertussis, Actinomycetales Infections, Bacterial Infections, +20 more
Locations
  • GSK Investigational Site Carlton, Victoria, Australia
  • GSK Investigational Site Calgary, Alberta, Canada
  • GSK Investigational Site Halifax, Nova Scotia, Canada
  • GSK Investigational Site Montreal, Quebec, Canada
View all 30 locations
View Trial Details
Completed

Immunogenicity, Safety of GSKs Tdap Vaccine Boostrix When Coadministered With GSKs Influenza Vaccine Fluarix in Adults

NCT00385255

Conditions
Acellular Pertussis, Actinomycetales Infections, Bacterial Infections, +13 more
Locations
  • GSK Investigational Site Huntsville, Alabama, United States
  • GSK Investigational Site Chandler, Arizona, United States
  • GSK Investigational Site Mesa, Arizona, United States
  • GSK Investigational Site Phoenix, Arizona, United States
View Trial Details
Completed

Evaluation of the Immunogenicity, Safety and Reactogenicity of the Combined DTPa-IPV Vaccine in Healthy Infants

NCT00290342

Conditions
Acellular Pertussis, Actinomycetales Infections, Bacterial Infections, +7 more
Locations
  • GSK Investigational Site Bucheon-si, South Korea
  • GSK Investigational Site Daegu, South Korea
  • GSK Investigational Site Gwangju, South Korea
  • GSK Investigational Site Incheon, South Korea
View Trial Details
Completed

Immunogenicity and Safety of Kinrix + (Measles Mumps Rubella) MMR Vaccine With and Without Varicella Vaccine in Healthy Children 4-6 Years

NCT00871117

Conditions
Acellular Pertussis, Actinomycetales Infections, Bacterial Infections, +7 more
Locations
  • GSK Investigational Site Antioch, California, United States
  • GSK Investigational Site Daly City, California, United States
  • GSK Investigational Site Hayward, California, United States
  • GSK Investigational Site Redwood City, California, United States
View Trial Details
Completed

Safety and Immunogenicity of New Formulations of GlaxoSmithKline Biologicals' DTPa-HBV-IPV/Hib Vaccine (GSK217744)

NCT01248884

Conditions
Acellular Pertussis, Actinomycetales Infections, Bacterial Infections, +32 more
Locations
  • GSK Investigational Site Santo Domingo, Dominican Republic
  • GSK Investigational Site Santo Domingo, Distrito Nacional, Dominican Republic
  • GSK Investigational Site Espoo, Finland
  • GSK Investigational Site Helsinki, Finland
View all 16 locations
View Trial Details
Completed

Study of GlaxoSmithKline Biologicals' GSK2202083A Vaccine in Healthy Infants

NCT01090453

Conditions
Acellular Pertussis, Actinomycetales Infections, Bacterial Infections, +33 more
Locations
  • GSK Investigational Site Vancouver, British Columbia, Canada
  • GSK Investigational Site Winnipeg, Manitoba, Canada
  • GSK Investigational Site Hamilton, Ontario, Canada
  • GSK Investigational Site Aix-en-Provence, France
View all 34 locations
View Trial Details

Related conditions